明發集團(00846.HK):餘下中國附屬公司的董事會建議重組事宜將於8月底完成
格隆匯6月30日丨明發集團(00846.HK)披露容有關公司中國附屬公司各自的董事會建議重組事宜的最新進展情況,於公吿日期:
兩間中國附屬公司已向地方負責監管機構提呈其董事變更申請並正在等待反饋及批准;及
六間中國附屬公司("餘下中國附屬公司")正在準備申請變更董事的文件。
董事會一直跟進上述事宜的進展,並獲吿知直至公吿日期,正持續與相關少數股東及╱或地方負責監管機構聯繫,而聯絡過程需要額外時間。基於與各相關少數股東及地方負責監管機構之最新聯繫進展情況,公司的最新估計為,餘下中國附屬公司的董事會建議重組事宜將於2021年8月底完成。董事會將繼續監察進展情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.